“With generative AI becoming more capable of producing remarkably convincing radiology reports, there’s a greater risk of fabricated reports being used to falsify medical histories and support fraudulent claims,” the team cautioned.
Providers are up to three times more likely to trust the opinion of humans over AI, even when the algorithm is proven to detect more cancerous lesions than radiologists.
Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.